HK1246650A1 - 抗病毒免疫的方法和組合物 - Google Patents

抗病毒免疫的方法和組合物

Info

Publication number
HK1246650A1
HK1246650A1 HK18106115.7A HK18106115A HK1246650A1 HK 1246650 A1 HK1246650 A1 HK 1246650A1 HK 18106115 A HK18106115 A HK 18106115A HK 1246650 A1 HK1246650 A1 HK 1246650A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
immunization against
against virus
virus
Prior art date
Application number
HK18106115.7A
Other languages
English (en)
Inventor
翁启惠
馬徹
王正琪
陳俊叡
Original Assignee
中央研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中央研究院 filed Critical 中央研究院
Publication of HK1246650A1 publication Critical patent/HK1246650A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
HK18106115.7A 2009-03-27 2018-05-10 抗病毒免疫的方法和組合物 HK1246650A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16438509P 2009-03-27 2009-03-27
US16438909P 2009-03-28 2009-03-28
US16438809P 2009-03-28 2009-03-28
US16438709P 2009-03-28 2009-03-28
US31367610P 2010-03-12 2010-03-12

Publications (1)

Publication Number Publication Date
HK1246650A1 true HK1246650A1 (zh) 2018-09-14

Family

ID=42781945

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106115.7A HK1246650A1 (zh) 2009-03-27 2018-05-10 抗病毒免疫的方法和組合物

Country Status (15)

Country Link
US (3) US8741311B2 (zh)
EP (1) EP2411049B1 (zh)
KR (2) KR20170124619A (zh)
CN (2) CN107375919B (zh)
AU (2) AU2010229675B2 (zh)
BR (1) BRPI1012635A2 (zh)
CA (1) CA2756206A1 (zh)
CL (2) CL2011002354A1 (zh)
CO (1) CO6460701A2 (zh)
ES (1) ES2784189T3 (zh)
HK (1) HK1246650A1 (zh)
IL (2) IL215430A (zh)
MX (1) MX2011009930A (zh)
TW (1) TWI510247B (zh)
WO (1) WO2010111687A2 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756206A1 (en) 2009-03-27 2010-09-30 Academia Sinica Methods and compositions for immunization against virus
US20120219584A1 (en) * 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
US8956859B1 (en) * 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
CN102955589A (zh) * 2011-08-18 2013-03-06 宸鸿光电科技股份有限公司 触控面板的控制系统及控制方法
CN103018442B (zh) * 2011-09-23 2014-11-19 华中农业大学 猪肺炎支原体间接elisa抗体检测试剂盒及应用
EP2852396A4 (en) * 2012-05-23 2016-04-20 Univ Leland Stanford Junior INFLUENZA VACCINE CONSTRUCTS
KR20150063079A (ko) * 2012-09-28 2015-06-08 엘리스 클라인 감염성 질환의 치료를 위한 글리코시다아제 요법
CN103353526B (zh) * 2013-07-23 2015-10-21 河南枫华生物科技有限公司 一种检测猪伪狂犬抗体的试剂盒
CN104391112A (zh) * 2014-05-27 2015-03-04 中国农业科学院特产研究所 检测牛副流感病毒3型抗体的表达蛋白及elisa试剂盒
CN104195113B (zh) * 2014-08-07 2017-05-03 扬州大学 H5亚型禽流感疫苗候选株rS‑156‑/170+/181‑及其构建方法及应用
CN104195114A (zh) * 2014-09-05 2014-12-10 青岛易邦生物工程有限公司 一种禽肺病毒及其应用
US10675345B2 (en) 2014-12-30 2020-06-09 Georgia State University Research Foundation, Inc. Recombinant influenza virus vaccines for influenza
EP3103474A1 (en) * 2015-06-12 2016-12-14 Institut Pasteur Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses
PT3718565T (pt) 2015-10-22 2022-07-20 Modernatx Inc Vacinas contra vírus respiratórios
WO2017151655A1 (en) * 2016-02-29 2017-09-08 The Curators Of The University Of Missouri Cancer immune-based therapy
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
CN107973840A (zh) * 2017-01-13 2018-05-01 浙江海隆生物科技有限公司 CHO细胞表达牛传染性病气管炎病毒gD蛋白及其亚单位疫苗的制备和应用
EP3568157A4 (en) * 2017-01-13 2021-01-06 National Research Council of Canada METHOD FOR OPTIMIZING THE PEPTIDE IMMUNO-EPITOP BY GLYCOSYLATION, OPTIMIZED PEPTIDE THEREOF AND ITS USE FOR CONJUGATE VACCINES
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
WO2019063844A1 (en) * 2017-09-29 2019-04-04 Universiteit Antwerpen VACCINATION AGAINST SYNCYTIAL RESPIRATORY VIRUS
US11648304B2 (en) 2017-11-03 2023-05-16 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CA3084605A1 (en) 2017-11-30 2019-06-06 Takeda Vaccines, Inc. Method for inactivating zika virus and related methods
JP7329529B2 (ja) * 2018-03-28 2023-08-18 サノフィ パスツール インコーポレイテッド ヘマグルチニンを含む広範に防御的なワクチン組成物を生成する方法
CN109134624A (zh) * 2018-09-19 2019-01-04 天康生物股份有限公司 禽流感病毒血凝素抗原及其制备方法、应用和禽流感疫苗
CN109307772B (zh) * 2018-10-12 2021-12-24 华南农业大学 一种伪狂犬病毒gE和gB IgG抗体双重荧光微球免疫学检测方法
US20210401969A1 (en) * 2018-10-29 2021-12-30 Emory University Rsv virus-like particles and methods of use thereof
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
CN110184298B (zh) * 2019-05-15 2023-05-16 武汉璟泓科技股份有限公司 Hiv突变型表面糖蛋白及其纳米化抗原与制备方法
KR102393872B1 (ko) * 2019-08-28 2022-05-04 엠브릭스 주식회사 바이러스 외피를 손상시키는 m2 단백질 유래 항바이러스 펩타이드 및 그의 용도
CN110568190A (zh) * 2019-08-30 2019-12-13 深圳国际旅行卫生保健中心 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法
US20230398090A1 (en) * 2020-03-27 2023-12-14 Beech Tree Labs, Inc. Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof
MX2022014013A (es) * 2020-05-08 2023-01-30 Academia Sinica Vacunas quimericas contra la influenza.
CN113322271A (zh) * 2020-06-24 2021-08-31 西南交通大学 基于酵母表面展示系统的covid-19亚单位疫苗
WO2022124800A1 (ko) 2020-12-11 2022-06-16 (주)에이피테크놀로지 푸코실락토스를 유효성분으로 함유하는 항바이러스 조성물
CN114632089B (zh) * 2020-12-16 2024-08-13 北京瑞博开拓医药科技有限公司 含酰基糖胺基团化合物在制备治疗新型冠状病毒肺炎药物中的应用及疾病的治疗方法
EP4285105A1 (en) * 2021-01-29 2023-12-06 Flowmetric Life Sciences, Inc. Detecting sars-cov-2 and other infective agents
WO2022212714A1 (en) 2021-04-01 2022-10-06 Becton Dickinson And Company Methods for enhancing specificity and sensitivity of group a streptococcus immunoassay
CA3189465A1 (en) * 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
WO2023131872A2 (en) * 2022-01-04 2023-07-13 Bartov Noa Rectal administration techniques
CN114106207B (zh) * 2022-01-24 2022-04-26 诺未科技（北京）有限公司 Ccl5的用途
WO2023178228A1 (en) * 2022-03-16 2023-09-21 Pharmalectin, Inc. Lectin-binding carbohydrates for treating viral infections
CN117229370A (zh) * 2022-06-08 2023-12-15 中科南京生命健康高等研究院 H5n6禽流感广谱性疫苗的开发及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953592A (en) 1973-09-27 1976-04-27 Recherche Et Industrie Therapeutiques (R.I.T.) Live influenza virus vaccines and preparation thereof
US4318903A (en) 1978-07-12 1982-03-09 Smithkline-Rit Live influenza virus vaccine and the preparation thereof
US4338296A (en) 1979-10-16 1982-07-06 Smithkline-Rit Influenza virus and process of producing a vaccine therefrom
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0203177A4 (en) * 1984-11-29 1987-04-28 Scripps Clinic Res POLYPEPTIDES AND ANTIBODIES AGAINST DEGGLYCOSILIZED VIRAL GLYCOPROTEINS.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
DE3619720A1 (de) 1986-06-12 1987-12-17 Behringwerke Ag Hauptglykoprotein des menschlichen cytomegalovirus, seine herstellung und verwendung
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6103238A (en) * 1992-03-13 2000-08-15 President And Fellows Of Harvard College Selectively deglycosylated human immunodeficiency virus type 1 envelope vaccines
EP0979867A3 (en) * 1993-11-04 2007-06-13 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
DK0721505T4 (da) 1994-07-29 2006-08-14 Innogenetics Nv Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse
US20020045594A1 (en) * 1997-02-14 2002-04-18 Merck & Co., Inc. Polynucleotide vaccine formulations
AU6535898A (en) * 1997-03-14 1998-10-12 President And Fellows Of Harvard College Glycosylation deficient siv and hiv envelope glycoproteins
US6908617B1 (en) * 1997-11-10 2005-06-21 Dana-Farber Cancer Institute, Inc. Glycosylated modified primate lentivirus envelope polypeptides
EP1137401B1 (en) 1998-12-09 2005-11-23 Chiron Corporation Administration of neurotrophic agents to the central nervous system
ES2293898T3 (es) 1999-05-12 2008-04-01 Statens Serum Institut Combinaciones de adyuvantes para inmunizacion y vacunas.
FR2799974B1 (fr) * 1999-10-25 2001-11-30 Aventis Pasteur Complexe deglycosyle proteine env/cd4 et son utilisation pour la vaccination contre le vih
IL150109A0 (en) 1999-12-09 2002-12-01 Chiron Corp Method for administering a cytokine to the central nervous system and the lymphatic system
JP2003528925A (ja) 2000-04-03 2003-09-30 ザ ユニバーシティー オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エドゥケーション 低温適応型ウマインフルエンザウイルス
AU7765801A (en) * 2000-06-30 2002-01-08 Flanders Interuniversity Inst Protein glycosylation modification in pichia pastoris
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
EP1390397B1 (en) * 2001-05-25 2008-10-01 Dobeel Corp. Pre-s protein of hepatitis b virus (hbv) as an adjuvant and a component of hbv vaccine
CA2468295C (en) 2001-11-28 2010-08-03 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
US20030124652A1 (en) 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US7442375B2 (en) * 2002-12-13 2008-10-28 Case Western Reserve University Compositions of beta-defensin inducing agents
GB0416487D0 (en) * 2004-07-23 2004-08-25 Isis Innovation Modified virus
AU2005322353B2 (en) 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
US20060251680A1 (en) 2005-03-16 2006-11-09 United Therapeutics Corporation Mannose immunogens for HIV-1
CA2615020A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Adjuvation through cross-.beta. structure
FR2889572B1 (fr) * 2005-08-03 2009-01-30 Eaton Sam Sa Monegasque Electrovanne de regulation de pression a blocs electromagnetique et hydraulique distincts
US8206949B2 (en) 2005-11-15 2012-06-26 Glycofi, Inc. Production of glycoproteins with reduced O-glycosylation
ES2310072B1 (es) 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
CU23544A1 (es) 2006-02-28 2010-06-17 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
CN106237316A (zh) 2006-03-07 2016-12-21 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
EP2001358B1 (en) 2006-03-27 2016-07-13 University Of Maryland, Baltimore Glycoprotein synthesis and remodeling by enzymatic transglycosylation
US7507411B2 (en) * 2006-06-23 2009-03-24 University Of Saskatchewan Attenuated influenza NS1 variants
WO2007150054A2 (en) 2006-06-24 2007-12-27 Mrugesh Shah Immunogenic compositions having altered glycosylations
KR20090050056A (ko) 2006-08-14 2009-05-19 메사츄세츠 인스티튜트 어브 테크놀로지 헤마글루티닌 폴리펩티드 및 시약 그리고 방법
EP2069393A2 (en) * 2006-10-10 2009-06-17 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Avian influenza vaccine
WO2008143717A2 (en) 2007-01-18 2008-11-27 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
US7928068B2 (en) 2007-01-31 2011-04-19 New York University Methods for using GEP, a chondrogenic growth factor and target in cartilage disorders
TW200907058A (en) 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
CA2756206A1 (en) 2009-03-27 2010-09-30 Academia Sinica Methods and compositions for immunization against virus
CN102803292A (zh) 2009-04-20 2012-11-28 辉瑞公司 蛋白质糖基化的控制及其相关组合物和方法
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法

Also Published As

Publication number Publication date
US20100247571A1 (en) 2010-09-30
TWI510247B (zh) 2015-12-01
IL215430A (en) 2016-11-30
KR20170124619A (ko) 2017-11-10
WO2010111687A2 (en) 2010-09-30
CL2014002415A1 (es) 2015-01-02
IL248607A (en) 2016-12-29
KR101793195B1 (ko) 2017-11-02
EP2411049A2 (en) 2012-02-01
US8741311B2 (en) 2014-06-03
US10307475B2 (en) 2019-06-04
US20150335728A1 (en) 2015-11-26
US20200046826A1 (en) 2020-02-13
CN107375919B (zh) 2022-07-29
IL248607B2 (en) 2023-05-01
TW201102084A (en) 2011-01-16
WO2010111687A3 (en) 2012-07-05
MX2011009930A (es) 2012-05-08
CN103200961A (zh) 2013-07-10
BRPI1012635A2 (pt) 2016-06-21
IL215430A0 (en) 2011-12-29
IL248607B1 (en) 2023-01-01
CA2756206A1 (en) 2010-09-30
AU2010229675B2 (en) 2016-02-25
AU2010229675A1 (en) 2011-10-27
EP2411049B1 (en) 2020-01-15
EP2411049A4 (en) 2013-12-04
CN107375919A (zh) 2017-11-24
AU2016203431B2 (en) 2018-03-08
CL2011002354A1 (es) 2012-06-15
ES2784189T3 (es) 2020-09-23
US11672853B2 (en) 2023-06-13
CO6460701A2 (es) 2012-06-15
AU2016203431A1 (en) 2016-06-16
KR20140014348A (ko) 2014-02-06
CN103200961B (zh) 2017-10-27

Similar Documents

Publication Publication Date Title
HK1246650A1 (zh) 抗病毒免疫的方法和組合物
HK1246715A1 (zh) 用於靶向熱調節的組合物和方法
EP2451795A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE EFFICACY OF A VIRUS
IL219891A0 (en) Lipopeptide compositions and related methods
HK1173657A1 (zh) 免疫組合物和方法
EP2504428A4 (en) METHOD AND COMPOSITIONS FOR TREATING OXALATE-MEDIATED SUFFERING
IL208445A0 (en) Compositions and methods for immunotherapy
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
EP2285405A4 (en) VACCINE COMPOSITIONS AND METHODS
EP2515940A4 (en) IMMUNOGENIC COMPOSITIONS AND CORRESPONDING METHODS
IL214127A0 (en) Vaccine compositions
IL214211A0 (en) Stable vaccine compositions and methods for preparing the same
EP2498815A4 (en) VACCINE COMPOSITION
ZA201403281B (en) Methods and compositions for neuroprotection
GB0901494D0 (en) Compositions and Methods
IL220308A0 (en) Vaccine compositions
GB0909720D0 (en) Compositions and methods
GB0908498D0 (en) Compositions and methods
GB0907616D0 (en) Methods and compositions
GB0903913D0 (en) Compositions and methods
GB0807579D0 (en) Vaccine composition and method
GB0900943D0 (en) Vaccine compositions